Market Intelligence

Report Categories

View All

Earnings Reports

Track quarterly earnings performance, beat/miss analysis, and EPS surprises across all sectors

Hot Topics

Stay updated with the latest market trends, industry news, and emerging investment themes

Market Overview

Comprehensive market analysis including index performance, sector rotation, and fund flows

Stock Analysis

In-depth analysis of individual stocks with fundamental and technical insights

Recent Articles

View All

IBM Shares Surge 27 Billion After Trump Administrations 2 Billion Quantum Computing Push Ofcom Flags Safety Concerns for Kids on TikTok and YouTube Enbridge Receives Higher Price Target as Cash Flow Outlook Remains Strong Bond Market Suggests Fed May Be Behind the Curve on Inflation as Kevin Warsh Assumes Leadership Walmart Warns US Shoppers Are Cutting Spending as Higher Fuel Costs Bite VTVT Q1 2026 Earnings Massive EPS Beat Driven by OneTime Items Stock Declines GALT Q1 2026 Earnings EPS Misses Estimates as Clinical Development Continues Uber Q1 2026 Earnings Significant EPS Miss Amid Operational Adjustments THO Q1 2026 Earnings Massive EPS Surprise of 831 Drives Stock Higher Immunome Q1 2026 Earnings EPS Beats Estimates Despite No Revenue Stock Declines Hercules Capital HTGC Rallies 209 as Stock Approaches Key Resistance Level Lakeshore Acquisition III Corp Rights LCCCR Holds Steady at 024 Amid Limited Activity Kinsale Capital KNSL Holds Near 310 as Modest Decline Tests Support Zone Jumia Technologies JMIA Rallies 244 as ECommerce Stock Tests Resistance Near 750 CurtissWright Corp CW Emerges as Potential Beneficiary Amid Rising Geopolitical Tensions Bahrain Minister Hails UKGulf Trade Pact as Monumental Achievement Market Expert Sunil Subramaniam Sees Q1 Earnings as Key Driver Flags NearTerm Risks Carvana CVNA Analyst Price Targets Revised Following Recent Stock Split

External Links

SP 500 Edges Higher as Healthcare and Tech Lead Communication Services Lags Verrica Pharmaceuticals VRCA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Sees Modest Stock Gain